论文部分内容阅读
目的分析全国(未包括香港、澳门特别行政区和台湾地区,下同)疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)信息管理系统中,接种疫苗后格林-巴利综合征(Guillain-Barre Syndrome,GBS)的发生特征,评价接种疫苗后GBS的发生风险。方法通过收集全国2009～2010年AEFI信息管理系统中诊断为GBS的AEFI个案数据,采用描述性流行病学方法对相关指标进行分析。结果全国2009～2010年AEFI信息管理系统共收到GBS的AEFI个案报告32例,男、女性别发病比为1∶1,各年龄组均有发生,以<15岁儿童为主,发病季节以秋冬季多见。GBS涉及9种疫苗,报告例数和估算报告发生率均以接种甲型H1N1流行性感冒疫苗最高,9种疫苗接种后GBS的报告发生率在0.01/100万剂～0.19/100万剂。在32例GBS中,20例(62.50%)分类为预防接种异常反应。在20例GBS预防接种异常反应中,与接种疫苗的时间关联最强(发生在接种疫苗后1～6周)的报告数为5例,占25%。结论预防接种后发生的GBS极为罕见,接种疫苗后的GBS报告发生率远低于全病因的GBS发病率,未发现接种疫苗后GBS发生的风险增高,应继续加强GBS的AEFI监测、调查诊断和处置,正确认识接种疫苗后GBS的风险,以减少其对免疫规划的影响,并加强GBS的基础发病率研究,为评价接种疫苗后GBS的风险提供参考。
Objective To analyze the prevalence of post-vaccination Guillain-Barre Syndrome (AEFI) information management system in the country (excluding Hong Kong, Macau SAR and Taiwan, the same below) , GBS), and evaluate the risk of GBS after vaccination. Methods By collecting data of AEFI cases diagnosed as GBS from 2009 to 2010 in AEFI information management system, the descriptive epidemiological method was used to analyze the related indicators. Results AEFI information management system from 2009 to 2010 in China received a total of 32 cases of AEFI reported by GBS. The incidence rate of male and female was 1: 1 in all age groups. Most of children aged <15 years old, More common in autumn and winter. GBS involved nine kinds of vaccines, the number of reported cases and the estimated incidence of the report were the highest vaccination against influenza A (H1N1). The incidence of GBS after the nine vaccines was reported was 0.01 / 1 million doses to 0.19 / 1 million doses. In 32 cases of GBS, 20 cases (62.50%) were classified as vaccination abnormalities. Among the 20 GBS vaccination anomalies, there were 5 cases (25%) reporting the strongest association with vaccination time (1 to 6 weeks after vaccination). Conclusion The incidence of GBS after vaccination is extremely rare. The incidence of GBS after vaccination is much lower than that of all-cause GBS. The risk of GBS after vaccination is not found to be increased. The AEFI monitoring of GBS should be further strengthened. Disposal and correct understanding of the risk of GBS after vaccination in order to reduce its impact on the immunization program and to strengthen the study of the basic incidence of GBS to provide a reference for assessing the risk of GBS after vaccination.